CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Non InterventionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2975 questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)

The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and stillbirth; 3) follow the pregnancy course and perinatal outcome of confirmed COVID-19-infected pregnant cases; 4) determine the risk and characteristics of vertical transmission; and 5) evaluate the placental barrier, immune response and fetal damage in vertical transmission of SARS-CoV-2. A series of longitudinal and cross-sectional observational studies, and a laboratory-based study will be conducted to fulfil the 5 objectives.

NCT04465474 COVID-19 Other: Non Intervention
MeSH:Coronavirus Infections

Primary Outcomes

Description: Mother

Measure: Seroconversion during pregnancy - DSS1

Time: At DSS1 (Around 11-13 weeks gestation)

Description: Mother

Measure: Seroconversion during pregnancy - At delivery

Time: At Delivery

Description: Mother (1st); Mother and abortus/stillborn baby(2nd)

Measure: Pregnancy loss

Time: At pregnancy loss

Description: Mother and Baby

Measure: Pregnancy course and perinatal outcome

Time: From date of recruited until the date of delivery

Description: Mother and Baby

Measure: Vertical transmission

Time: At Newborn 0 hours of life, mother immediately after delivery

Description: Mother and Baby

Measure: Vertical transmission

Time: At Newborn 7 days of life

Description: Mother and Baby

Measure: Vertical transmission

Time: At Newborn 14 days of life

Description: Mother and Baby

Measure: Vertical transmission

Time: At Newborn 6 months of life

Description: Mother and Baby

Measure: Vertical transmission

Time: At Newborn 18 months of life

Description: Mother and Baby

Measure: Potential mechanisms for vertical transmission 1) placental barrier, 2) immune response and 3) fetal damage of vertical transmission and mechanism in SARS-CoV-2 infection.

Time: through study completion, up to 2 years


No related HPO nodes (Using clinical trials)